Sarepta (NASDAQ: SRPT) R&D president earns 1,875 performance stock units

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. reported that executive Louise Rodino-Klapac, President of R&D and Tech Ops, acquired 1,875 Performance Stock Units (PSUs) on the basis of a prior equity award. These PSUs were earned under a PSU grant originally awarded on March 1, 2024.

The number of PSUs earned reflects the compensation committee’s assessment of the company’s achievement of specified milestones in that award. Following this transaction, Rodino-Klapac holds a total of 8,125 PSUs. The earned PSUs are scheduled to vest on March 1, 2026, provided she continues to serve the company through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	02/25/2026		A		1,875		(1)	(1)	Common Stock	1,875	(1)	8,125	D

Explanation of Responses:

1. Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report for Louise Rodino-Klapac?

Sarepta reported that Louise Rodino-Klapac acquired 1,875 Performance Stock Units. These units were earned under a prior PSU award, based on milestone achievement determined by the compensation committee, and increase her total PSU holdings to 8,125 units.

When were the Sarepta Therapeutics PSUs originally granted to Louise Rodino-Klapac?

The 1,875 earned Performance Stock Units relate to a PSU award granted on March 1, 2024. The award’s payout depended on Sarepta’s achievement of prescribed milestones, which the compensation committee later evaluated to determine the number of PSUs actually earned.

How many Sarepta Therapeutics PSUs does Louise Rodino-Klapac hold after this Form 4?

After this transaction, Louise Rodino-Klapac holds 8,125 Performance Stock Units. This total reflects the 1,875 PSUs earned under the March 1, 2024 award, combined with her previously reported PSU holdings, all reported as directly owned.

What conditions apply to the vesting of Louise Rodino-Klapac’s earned Sarepta PSUs?

The earned Performance Stock Units will vest on March 1, 2026. Vesting is conditioned on Louise Rodino-Klapac continuing to provide service to Sarepta Therapeutics through that date, meaning she must remain with the company for the units to fully vest.

What does the compensation committee’s milestone assessment mean for Sarepta’s PSU award?

The compensation committee reviewed Sarepta’s achievement of specified milestones under the PSU award. Based on this assessment, it determined that 1,875 shares were earned, converting performance targets into actual PSUs credited to Louise Rodino-Klapac’s direct equity-based compensation.

Was there any purchase price for the Sarepta Therapeutics PSUs granted to Louise Rodino-Klapac?

The Form 4 shows a price per unit of $0.00 for the 1,875 PSUs. This indicates the units were granted as part of compensation, rather than bought on the open market, reflecting non-cash, equity-based incentive pay tied to performance goals.